Completion of lung cancer screening may be associated with demographic factors, according to study results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by Christine Neslund-Dudas, PhD, of the Henry Ford Health System, Detroit, Michigan, and colleagues.
The study was a retrospective analysis involving health systems included in the Lung Population-Based Research to Optimize the Screening Process (PROSPR) Consortium. Of the patients for whom there were records of lung cancer screening orders, the researchers evaluated adherence to orders for baseline, low-dose computed tomography (LDCT). Patient characteristics, including smoking history, were also analyzed in logistic regression analyses. Completion of LDCT within 90 days of an order for screening was the primary outcome.
A total of 12,661 patients for whom an LDCT had been ordered were evaluated, among whom 62% underwent LDCT within 90 days of an order for screening. Male sex, age, presence of comorbidities, and former smoking status were all factors linked to the likelihood of completing a screening LDCT. Socioeconomic level and race also showed apparent differences in adherence to LDCT uptake.
Patients who were Asian/Pacific Islander or Hispanic were more likely than non-Hispanic White patients to have completed a screening LDCT. In an analysis of an interaction between race and sex, non-Hispanic Black men showed a significantly lower likelihood of completing a screening LDCT than non-Hispanic White men did. However, this pattern was not seen among women.
“Since Black [men] have historically had a higher burden of lung cancer mortality, this disparity in screening uptake is concerning, and if it continues, we should anticipate increases and disparities in mortality for Black men,” Dr Neslund-Dudas concluded in her presentation.
Disclosure: This study was supported by the US National Institutes of Health. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies.
Please see the original reference for a full list of authors’ disclosures.
Neslund-Dudas C, Tang A, Alleman E, et al. Completion of lung cancer screening after a baseline order for LDCT at five diverse health systems. J Clin Oncol. 2021;39:(suppl 15; abstr 10506). doi:10.1200/JCO.2021.39.15_suppl.10506